These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study].
    Author: Cui CL, Chi ZH, Yuan XQ, Lian HY, Si L, Guo J.
    Journal: Ai Zheng; 2008 Aug; 27(8):845-50. PubMed ID: 18710619.
    Abstract:
    BACKGROUND & OBJECTIVE: The therapeutic effect on melanoma metastasizing to liver is poor. Researches have demonstrated that hepatic intra-arterial bio-chemotherapy can improve the treatment efficacy of metastatic melanoma. This study was to investigate hepatic intra-arterial bio-chemotherapy for the treatment and survival of patients with liver metastasis from melanoma. METHODS: Twenty-one patients with liver metastasis from melanoma were treated with hepatic intra-arterial infusion of dacarbazine (250 mg/m(2)) from the first to the fifth day, and fotemustine (100 mg/m(2)) at the sixth and fourteenth day, followed by adoptive transfer of autologous cytokine-induced killer cells and administration of interleukin-2 and 150 ug granulocyte/macrophage colony stimulating factor for 10-12 days. The treatment was repeated every 28 days. The overall survival, response and toxicity were analyzed. RESULTS: Seventeen of twenty-one patients were evaluable. One achieved complete remission (CR), one achieved partial remission (PR), six had stable disease (SD) and nine had progression disease (PD).The disease control rate was 47.06% (8/17), with a median progression free survival (PFS) of 3.76 months and a medium overall survival (OS) of 6 months. Treatment related complications were mainly myelosuppression (grade III-IV), occurring in 38.1% (8/21) patients. CONCLUSIONS: Hepatic intra-arterial chemotherapy can improve the disease control rate of progressive melanoma. It tends to prolong the PFS and OS with tolerable toxicity in patients with liver metastasis from melanoma.
    [Abstract] [Full Text] [Related] [New Search]